sylvain giraud
A Brussels bureaucrat / @EU_Health policy / Effective Accessible Resilient Health Systems / views expressed are my own / RT not endorsement /đ
Last synced from Twitter 20m ago
Political parties focus on crisis in healthcare
Universal healthcare, GP services and mental health were discussed by the health spokespersons for Fine Gael, Fianna FĂĄil, Sinn FĂ©in and the Social Democrats.
sylvain giraud
Ireland: Political parties focus on crisis in healthcare rte.ie/news/campaign-⊠via @rte
58m
Valrox, Potential Hemophilia A Gene Therapy, May Cost Up to $3...
BioMarin is considering pricing its hemophilia A gene therapy Valrox (valoctocogene roxaparvovec), should it be approved, at $2 million to $3 million. That range would make Valrox the worldâs most expensive one-time therapy. But, the company argues,...
sylvain giraud
Valrox, Potential Hemophilia A Gene Therapy, May Cost Up to $3 Million, BioMarin Says
60m
Immune discovery 'may treat all cancer'
Research is at an early stage but scientists said it had huge potential for destroying cancers.
Busting the health tourism myth: Migrants face fresh HIV risk in Europe
Europeâs draw is a better life. But increasingly, studies suggest migrants are infected with HIV after arrival, not before.
sylvain giraud
Busting the health tourism myth: Europeâs draw is a better life. But increasingly, studies suggest migrants are infected with HIV after arrival, not before. @politicoeurope
1h
Researchers Investigate the Novelty of Costly Drugs
A new study from Harvard Medical School researchers found that of the 27 active ingredients in 25 brand-name drugs with the highest Medicare spend in 2017, 11 (41%) of the ingredients had previously been approved by the US Food and Drug...
Germania, farmacie incentivate a vendere medicinali importati. Interrogazione di unâeurodeputata
Lâeurodeputata KateĆina KoneÄnĂĄ ha depositato unâinterrogazione sugli incentivi concessi alle farmacie tedesche che vengono medicinali importati (e meno cari).
FDA approval may not be as rigorous as it once was
Changes in U.S. Food and Drug Administration (FDA) procedures meant to speed app...
Eli Lilly to offer half-priced versions of two more insulin products
Eli Lilly and Co said on Tuesday it plans to sell two versions of insulin produc...
50% of biopharma CMOs say they don't know what customers want -
Itâs indisputable that one of the keys to growth is understanding what your customers want and delivering it
UK's NICE isn't convinced by Merck's Keytruda in head and neck cancer
There may be 33 new cases of head and neck cancer in the United Kingdom each day, but the region's cost-effectiveness watchdog NICE is not convinced by the data supporting Merck's flagship immunotherapy Keytruda in the patient population. On...
Agenzia del farmaco: Nicola Magrini direttore generale
Medico e farmacologo, attualmente Ăš segretario del Comitato per i farmaci essenziali dellâOrganizzazione mondiale della sanitĂ (Oms). Succede a Li Bassi
Mandatory use of international standard for the reporting side effects to improve safety medicines
Mandatory use of international standard for the reporting side effects to improve safety medicines
German drug assessment body not convinced by Bayer's cancer drug Vitrakvi
Germany's drug assessment body said that data provided by Bayer on its prec...
Pricing and reimbursement concern to remain the leading impediment to industry growth in 2020
In 2020, drug pricing pressure from regulators and payers will remain and aggressive negotiation tactics to drive down drug prices will continue, according to GlobalData,...
sylvain giraud
In 2020, drug pricing pressure from regulators and payers will remain and aggressive negotiation tactics to drive
14h
NICE leaves the âthe NHS doorâ open despite rejecting Bayerâs Vitrakvi
Initial guidance says drug is too costly but encourages further data
sylvain giraud
NICE leaves the âthe NHS doorâ open despite rejecting Bayerâs Vitrakvi pmlive.com/pharma_news/ni⊠via @pmlivecom
14h
Bayer's 'tumor-agnostic' cancer med Vitrakvi turned away in England, Germany
Bayer is among drugmakers marketing new "tumor-agnostic" medicines that target specific types of tumors, regardless of their location in the body. But the company's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and...